Glossary · Clinical

Gout / crystal arthropathy

Gout and related crystal arthropathies are inflammatory joint conditions caused by deposition of metabolic crystals—most commonly monosodium urate (MSU) in gout—triggering acute or chronic synovitis, tophi formation, and progressive joint destruction if untreated.

Verified May 8, 2026 · 6 sources ↓

Drawn from CMSICD10DataAAPCIcdcodesAafp

Definition

Source · Editorial summary grounded in 6 cited references ↓

Gout is the most prevalent crystal arthropathy, driven by sustained hyperuricemia that leads MSU crystals to precipitate in synovial fluid, cartilage, and periarticular soft tissue. Acute flares present as sudden-onset, exquisitely painful monoarthritis—classically the first metatarsophalangeal joint—with erythema, warmth, and swelling. Definitive diagnosis rests on polarized-light microscopy of aspirated joint fluid demonstrating needle-shaped, negatively birefringent MSU crystals, or on dual-energy CT (DECT) showing urate deposition.

The crystal arthropathy family extends beyond gout. Calcium pyrophosphate deposition (CPPD) disease produces rhomboid, weakly positively birefringent crystals and is coded separately under M11 (chondrocalcinosis, hydroxyapatite deposition disease, and other specified crystal arthropathies). Basic calcium phosphate (hydroxyapatite) crystals are associated with destructive large-joint arthropathy and periarthritis. Distinguishing the crystal type drives both treatment and coding—urate-lowering therapy is indicated for gout; CPPD management differs entirely.

Chronic gout (M1A.-) is distinguished from acute/idiopathic gout (M10.-) by the presence of tophi or ongoing urate-driven joint erosion. Tophi—hard nodular deposits of MSU crystals—typically develop after a decade of inadequately controlled hyperuricemia but can appear as early as two to three years after disease onset. Radiographic joint erosions with overhanging edges are characteristic late findings. The etiology of chronic gout also matters for code selection: idiopathic, drug-induced, renal-impairment-related, and other secondary causes each map to distinct subcategories under M1A.-.

Why it matters

Choosing between M10.- (acute/idiopathic gout) and M1A.- (chronic gout) has direct reimbursement and audit consequences: M1A.- codes require documentation of either tophi on exam or radiographic erosions, and they further bifurcate by etiology (idiopathic, drug-induced, renal impairment, other secondary). Submitting M10.9 (gout, unspecified) when the record supports a more specific code is a documented audit-risk trigger and a missed opportunity to capture disease severity accurately. For crystal arthropathies other than gout, defaulting to M11.9 (crystal arthropathy, unspecified) instead of specifying site and type (e.g., M11.271 for right-ankle chondrocalcinosis) risks claim denial under payers that require site specificity and can suppress quality-measure credit for chronic disease management.

Common mistakes

Where people most often go wrong with this concept.

Source · Editorial brief grounded in cited references ↓

Coding M10.9 (gout, unspecified) when the note documents acute idiopathic gout with MSU crystal confirmation—use the site-specific M10.0xx subcategory instead.
Using M10.- codes for chronic gout with tophi—tophi require the M1A.- category regardless of whether a flare is occurring.
Ignoring etiology when selecting M1A.-: drug-induced chronic gout (M1A.2-) and chronic gout due to renal impairment (M1A.3-) are distinct from idiopathic (M1A.0-) and must be supported by the documented underlying cause.
Conflating CPPD/chondrocalcinosis with gout and assigning M10.- codes—calcium pyrophosphate disease belongs under M11.1- or M11.2-, and the crystal type must be confirmed by synovial fluid analysis.
Omitting the 7th character for tophus status on M1A.- codes (the final digit '1' indicates with tophus, '0' indicates without), causing claim rejection or downcoding.
Failing to document laterality and joint site, leaving coders with only unspecified-site codes when billable site-specific codes exist.
Not ruling out septic arthritis in the documentation before assigning a crystal arthropathy code—concurrent infection materially changes coding and clinical management.

Related codes

Codes commonly involved when this concept appears in practice.

CPT

ICD-10

M10.00 M10.9 M11.00 M11.80 M11.9

Modifiers

RT Right side LT Left side 50 Bilateral procedure

Frequently asked questions

Source · Generated from the editorial pipeline, verified against 6 cited references ↓

01What is the difference between M10.- and M1A.- codes?

M10.- covers acute and idiopathic gout presentations; M1A.- covers chronic gout, defined by the presence of tophi or ongoing erosive disease. Using M10.- when tophi are documented is a coding error and an audit flag.

02Does a uric acid blood level alone support a gout diagnosis for coding purposes?

No. Hyperuricemia supports clinical suspicion but is not definitive. ICD-10 documentation guidelines require synovial fluid analysis showing MSU crystals, DECT confirmation of urate deposition, or a clinician's explicit diagnostic statement supported by consistent clinical findings.

03How do I code calcium pyrophosphate deposition (CPPD) disease differently from gout?

CPPD belongs under M11.1- (familial chondrocalcinosis) or M11.2- (other chondrocalcinosis), not under M10/M1A. The crystal type—confirmed by polarized microscopy showing weakly positively birefringent rhomboid crystals—is the determining factor.

04What does the 7th character on M1A.- codes indicate?

The final digit specifies tophus status: '0' = without tophus, '1' = with tophus (tophi). Both digits are required for a complete, billable M1A.- code. Omitting this character results in a non-billable code.

05Can gout and septic arthritis be coded together?

Yes, but only when both are independently confirmed. The infectious arthritis code takes sequencing priority, and both conditions must be explicitly documented by the treating clinician—never assumed or inferred by the coder.

06Which CPT codes are commonly billed alongside a gout diagnosis?

Arthrocentesis codes (20600–20615, by joint size) for aspiration and injection are the most frequent. Synovial fluid crystal analysis (89060) is billed when fluid is sent for polarized microscopy, and uric acid serum tests (83540/83550) accompany laboratory workup.

Sources & references

Editorial content was developed using the following public sources. Last verified May 8, 2026.

Mira AI Scribe

When Mira detects documentation of gout or crystal arthropathy, it evaluates four decision points before suggesting a code: 1. ACUTE vs. CHRONIC: If the note describes a flare without prior tophi or erosion history, Mira targets M10.-. If tophi are documented on exam or imaging, or if the note references prior erosive disease, Mira routes to M1A.- and flags the tophus 7th-character requirement. 2. ETIOLOGY: Mira scans for medication triggers (diuretics, cyclosporine, low-dose aspirin), renal impairment (eGFR flags or CKD diagnosis), or lead exposure. Confirmed drug association → M1A.2-; renal impairment → M1A.3-; other secondary → M1A.4-; no identifiable cause → idiopathic M1A.0- or M10.0-. 3. CRYSTAL TYPE: If the note references polarized microscopy, DECT, or synovial fluid, Mira checks whether crystals are MSU (gout, M10/M1A), calcium pyrophosphate (CPPD, M11.1-/M11.2-), or hydroxyapatite (M11.0-). A scribe note is inserted prompting the provider to confirm crystal type when only 'crystal arthropathy' appears without further specification. 4. SITE AND LATERALITY: Mira captures the documented joint and side to populate the most specific billable code, and alerts the provider if laterality is missing before the note is finalized. Mira will not auto-assign M10.9 or M11.9 without first querying for the missing specificity, and will insert a soft alert if concurrent joint infection language is detected alongside a crystal arthropathy code.

See Mira's approach